Immunotherapy-based targeting of MSLN <sup>+</sup> activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

Takahiro Nishio(University of California San Diego Medical Center), Tatiana Kisseleva(University of California San Diego)
Proceedings of the National Academy of Sciences
July 12, 2021
Cited by 29


Related Papers